Should a baseline electrocardiogram be obtained before starting gender-affirming testosterone therapy in a 27-year-old patient?

ECG Not Routinely Required for a 27-Year-Old Starting Gender-Affirming Testosterone

A baseline ECG is not necessary for a healthy 27-year-old patient starting gender-affirming testosterone therapy, as this falls outside standard cardiovascular screening recommendations and established testosterone monitoring guidelines do not include ECG as a baseline requirement.

Rationale Based on Guidelines

Testosterone Therapy Monitoring Standards

The Endocrine Society clinical practice guidelines for testosterone therapy 1, 2 provide comprehensive monitoring recommendations that do not include baseline ECG. Required baseline assessments include:

• Hematocrit measurement
• PSA and digital rectal exam (for patients ≥40 years with baseline PSA >0.6 ng/ml)
• Testosterone levels
• Bone mineral density (in specific cases with osteoporosis)

The absence of ECG from these detailed monitoring protocols is notable, as these guidelines specifically address cardiovascular safety monitoring through hematocrit surveillance rather than electrocardiographic screening.

ECG Indication Guidelines

ACC/AHA electrocardiography guidelines 3 classify ECG indications by age and risk:

• Class III (not indicated): Patients <30 years old with no risk factors for coronary artery disease
• Class I (indicated): Asymptomatic persons >40 years of age

Your 27-year-old patient falls into the age group where routine ECG is explicitly not recommended unless cardiovascular risk factors or symptoms are present.

The guidelines do note that ECG is Class I indicated "to assess the response to the administration of any agent known to result in cardiac abnormalities or ECG abnormalities" 3. However, testosterone at therapeutic doses for gender-affirming care is not classified among agents "known to produce cardiovascular effects" in the same category as chemotherapeutic agents like doxorubicin.

Emerging Evidence on ECG Changes

Recent research reveals that gender-affirming testosterone does cause measurable ECG changes 4, 5:

• Increased J-point elevation and T-wave amplitudes
• Higher QRS amplitudes in precordial leads
• Development of "male pattern" ECG characteristics (89.7% prevalence post-treatment)
• Changes appear within weeks to months of therapy initiation

However, these changes represent physiologic adaptation toward male ECG phenotype rather than pathologic findings. The 2025 study 4 specifically recommends that "baseline and follow-up EKGs should be standardized when initiating HRT" to clarify structural and arrhythmogenic implications, but this represents emerging research rather than established clinical practice.

Cardiovascular Safety Context

The TRAVERSE trial and recent meta-analyses 6 demonstrate that testosterone therapy does not significantly increase major adverse cardiovascular events when appropriately prescribed and monitored. The primary cardiovascular concern is polycythemia (elevated hematocrit >54%), which is monitored through serial hematocrit measurements at baseline, 3-6 months, and annually 2.

Clinical Decision Algorithm

Obtain baseline ECG if:

• Age ≥40 years
• Known cardiovascular disease
• Cardiovascular symptoms (chest pain, palpitations, syncope)
• Cardiovascular risk factors (hypertension, diabetes, smoking, family history)
• Abnormal cardiovascular exam findings

Do NOT obtain baseline ECG if:

• Age <30 years AND
• No cardiovascular symptoms AND
• No cardiovascular risk factors AND
• Normal cardiovascular examination

For ages 30-39: Use clinical judgment based on individual risk profile

Common Pitfalls to Avoid

1. Over-screening young, healthy patients: The 27-year-old without risk factors does not benefit from routine ECG, and obtaining one may lead to false-positive findings requiring unnecessary follow-up
2. Confusing research recommendations with clinical standards: While 4 suggests baseline ECGs for research purposes, this has not been incorporated into clinical practice guidelines
3. Ignoring established monitoring: Focus on evidence-based monitoring (hematocrit at 3-6 months) rather than unvalidated screening

What Actually Matters for This Patient

Essential baseline assessments 2:

• Complete blood count (hematocrit baseline)
• Lipid panel
• Liver function tests
• Testosterone level (if checking baseline)

Follow-up at 3-6 months:

• Hematocrit (stop therapy if >54%)
• Testosterone level (adjust dose to mid-normal male range)
• Clinical assessment for adverse effects

The peri-operative care guideline 7 confirms that testosterone therapy improves quality of life and psychological functioning, with adverse effects including polycythemia, reduced HDL cholesterol, and potentially increased myocardial infarction risk—none of which are detected by baseline ECG screening.